Our core annular flow technology removes the viscosity constraint on formulation development, so concentration stops setting the terms of delivery.
Challenging formulations can mean hours in a hospital each week for patients with chronic diseases. Core annular flow makes those same formulations easy to deliver at home.
How CoFlo works
Conventional injection force rises with viscosity until it becomes impossible. Core annular flow breaks that relationship: a thin sheath of low-viscosity fluid shields the drug from the needle wall, where shear is highest, so concentration stops being a limit on delivery.
Up to
10,000 cP
Core annular flow is a physical solution that changes how a drug moves through the needle, not what the drug is. It serves as a platform across molecule types, volumes, and routes of administration. Sheath fluid shields the drug from the needle wall, reducing viscous drag.
Turn hours-long hospital infusions into 10-second injections at home.
Administer two formulations in a single injection.
Supports higher per-dose concentrations and conjugated formats.
Reduce injection volume and time without compromising complexity.
Carry candidates forward that viscosity would otherwise have ruled out. Gentle delivery for shear-sensitive compounds.
Core annular flow is a physical solution that changes how a drug moves through the needle, not what the drug is. It serves as a platform across molecule types, volumes, and routes of administration.
Sheath fluid is stored in a reservoir and is passively entrained to form the core annular flow.
Two syringes hold the sheath fluid and viscous fluid before they form a core annular flow in the CO-AXL Hub.
Adapts two syringes to form the core annular flow.
CEO & Co-founder
During his MIT PhD, Simon uncovered the fundamental fluidic phenomena that stabilize core-annular flows and built the prototypes behind CoFlo's platform. He draws on prior engineering experience at SpaceX and JPL to lead scale-up and commercialization.
CBO & Co-Founder
Vishnu is an experienced startup executive, having founded and lead several ventures including AgZen, where he scaled RealCoverage, a first-of-its-kind vision system for adjuvant spraying, to over 1 million acres internationally. Vishnu completed his PhD at MIT in interfacial phenomena, where he lead the development of early core-annular flow injectors.
Co-Founder & Chairman
Kripa is an MIT Professor of Mechanical Engineering whose work on interfacial phenomena has driven innovations in the medical, energy, water, and agriculture industries. He was previously a lead researcher and project leader at GE Global Research, and has co-founded several startups earning numerous awards.
Chief Medical Advisor, Ophthalmology
Dr. Moshfeghi is Professor of Ophthalmology and Chief of Retina at Stanford's Byers Eye Institute. He founded Stanford's vitreoretinal surgery fellowship and established SUNDROP, a telemedicine program for retinopathy of prematurity screening. As a practicing vitreoretinal surgeon, he brings direct experience with ophthalmic procedures and intravitreal delivery, along with experience in clinical trial oversight, steering committees, and ophthalmology product development.
MIT's flagship competition names one Grand Prize winner each year — the venture judged most promising across the Institute.
Read more: CoFlo wins the MIT $100K Entrepreneurship Competition(opens in a new tab)
Fierce Pharma on the core-annular approach to viscous drug delivery.
Read more: A double-barreled syringe for breezy biologics injections(opens in a new tab)
"Enhancing the Injectability of High Concentration Drug Formulations Using Core Annular Flows"
Read more: Publication in Advanced Healthcare Materials(opens in a new tab)
Publication
“High-Concentration, High-Viscosity Delivery with Core-Annular Flow”
Read more: Publication in ONdrugDelivery(opens in a new tab)